The EHC invites you to save the date for the European Rare and Inhibitor Network (ERIN) Summit 2024 taking place in Zagreb, Croatia, from November 28th to December 1st. It will be our second community-facing event aiming to offer a special time and space for all people with extremely rare bleeding disorders and people with haemophilia who have inhibitors, as well as their family members and caregivers.
Besides the community building aspect, the ERIN Summit will also offer possibilities to the participants to educate and empower themselves and to improve the quality of their lives. In addition, the Summit will be the place to spend time in a relaxing environment and enjoy social activities together.
Registration is now open – NMOs can nominate delegates until September 9th 2024!
What | European Rare and Inhibitor Network (ERIN) Summit |
When | 28 November – 1 December 2024 |
Where | Zagreb, Croatia |
For whom | We kindly invite each NMO to send up to 4 individuals in total from the below categories, respecting the outlined quota.
|
Language | English with Russian Interpretation |
Programme | Draft available here |
Registrations | This Workshop is exclusively open to EHC Members.Places are limited to four per NMO, and registrations will be done on a first-come, first-served basis until we reach the capacity.
Deadline for registrations: 9th September 2024. |
EHC Staff contact person | Fiona Brennan |
What is the ERIN?
In 2022, the EHC’s European Inhibitor Network (EIN) was expanded and became the European Rare and Inhibitor Network (ERIN), including extremely rare bleeding disorders, such as platelet disorders or extremely rare factor deficiencies.
The objective of the programme is to understand and prioritise the needs of people with ultra rare bleeding disorders, both at a community level as well as at a policy-making level, and to empower people with ultra rare bleeding disorders to drive the research in the field of ultra rare bleeding disorders thus taking steps to improve the treatment and care for these patient cohorts.